1312296-23-3

Upstream product

• 916047-82-0 tert-butyl [5'-chloro-1-(5-chloro-2-fluorobenzyl)-2,2',5-trioxospiro[imidazolidine-4,3'-indol]-1'(2'H)-yl]acetate 
• 916048-05-0 tert-butyl (5-chloro-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)acetate 
• 1262426-95-8 (+)-(S)-[5'-chloro-1-(5-chloro-2-fluorobenzyl)-2,2',5-trioxospiro[imidazolidine-4,3'-indol]-1'(2'H)-yl]acetic acid 
• 1312296-22-2 (+)-(S)-tert-butyl [5'-chloro-1-(5-chloro-2-fluorobenzyl)-2,2',5-trioxospiro[imidazolidine-4,3'-indol]-1'(2'H)-yl]acetate 
• 74-88-4 methyl iodide 
• 916048-13-0 tert-butyl 2-(5'-chloro-2,2',5-trioxospiro[imidazolidine-4,3'-indol]-1'(2'H)-yl)acetate 
• 17630-76-1 5-chloroindole 2,3-dione 
• 71916-91-1 5-chloro-2-fluorobenzyl bromide 

Relevant academic research and scientific papers

Optimization of the central core of indolinone-acetic acid-based CRTH2 (DP2) receptor antagonists

New spiroindolinone antagonists of CRTH2 are described. Following identification of insufficient stability in human plasma as an important liability of the lead compounds, replacement of the spirosuccinimide core with a spirohydantoin or spiropyrrolidinon